bioAffinity Technologies, Inc.

Equities

BIAF

US09076W1099

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 01:30:00 11/05/2024 am IST			5-day change	1st Jan Change
2 ^USD	-0.99%		-4.31%	+36.01%

01/04	BioAffinity Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
20/03	BioAffinity Technologies, Inc. announced that it has received $2.624 million in funding	CI

BioAffinity Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

November 15, 2023 at 01:42 am IST

bioAffinity Technologies, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 0.298484 million compared to USD 0.00115 million a year ago. Net loss was USD 2.29 million compared to USD 4.92 million a year ago. Basic loss per share from continuing operations was USD 0.26 compared to USD 1.17 a year ago.
For the nine months, sales was USD 0.319143 million compared to USD 0.002457 million a year ago. Net loss was USD 5.56 million compared to USD 6.48 million a year ago. Basic loss per share from continuing operations was USD 0.65 compared to USD 2.03 a year ago.

Latest news about bioAffinity Technologies, Inc.

BioAffinity Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04	CI
BioAffinity Technologies, Inc. announced that it has received $2.624 million in funding	20/03	CI
BioAffinity Technologies Closes $2.5 Million Equity Offerings	09/03	MT
BioAffinity Technologies, Inc. announced that it expects to receive $2.624 million in funding	06/03	CI
BioAffinity Technologies, Inc. Appoints Sandeep Bansal to Medical and Scientific Advisory Board	06/02	CI
Transcript : BioAffinity Technologies, Inc. - Special Call	10/01
BioAffinity Technologies, Inc. Appoints Jamie Platt, Ph.D., to its Board of Directors	05/12	CI
Earnings Flash (BIAF) BIOAFFINITY TECHNOLOGIES Posts Q3 Revenue $298,484	15/11	MT
BioAffinity Technologies, Inc. Provides Earnings Guidance for the Year 2023 and for the Next 12 Months(fourth quarter 2023 to third quarter 2024)	15/11	CI
BioAffinity Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
BioAffinity Technologies, Inc. Appoints Dallas J. Coleman as National Director of Sales	06/11	CI
BioAffinity Technologies Files Registration Statement for Planned Offering of Units at Assumed Price of $1.62 a Unit	21/23/21	MT
BioAffinity Technologies, Inc. Announces Board Changes	21/23/21	CI
Transcript : BioAffinity Technologies, Inc. - Special Call	20/23/20
BioAffinity Technologies Unit Acquires Precision Pathology Services Laboratory Assets; Shares Rise	19/23/19	MT
Transcript : BioAffinity Technologies, Inc. - Special Call	18/23/18
Earnings Flash (BIAF) BIOAFFINITY TECHNOLOGIES Reports Q2 Revenue $19,738	15/23/15	MT
BioAffinity Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
AMA Issues CPT Code for bioAffinity Technologiesâ€™ CyPathÂ® Lung Test for Early-Stage Lung Cancer	12/23/12	CI
BioAffinity Technologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
Earnings Flash (BIAF) BIOAFFINITY TECHNOLOGIES Posts Q1 Revenue $921	15/23/15	MT
BioAffinity Technologies, Inc. Announces CFO Changes	02/23/02	CI
Transcript : BioAffinity Technologies, Inc., Q4 2022 Earnings Call, Apr 03, 2023	03/23/03
BioAffinity Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	01/23/01	CI
BioAffinity Technologies Announces Publication of Peer-Reviewed Paper on Proprietary Beads Used in CyPath Lung for Noninvasive Detection of Early-Stage Lung Cancer	28/23/28	CI

Chart bioAffinity Technologies, Inc.

Duration

Period

More charts

Company Profile

bioAffinity Technologies, Inc. is a biotechnology company focused on commercializing noninvasive tests for the detection of early-stage cancer and lung disease. The Company addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. It develops noninvasive diagnostic tests using flow cytometry and automated analysis developed by artificial intelligence (AI). Its diagnostic tests analyze cell populations, including cancer and cancer-related cells, that are indicative of a specific diseased state. Its first product, CyPath Lung, is a noninvasive test that addresses the need for noninvasive detection of early-stage lung cancer. The CyPath Lung test enables physicians to identify patients who will likely benefit from timely intervention and more invasive follow-up procedures and those who are likely without lung cancer and should continue routine screening. CyPath Lung is marketed as a Laboratory Developed Test.

Sector

Medical Equipment, Supplies & Distribution

Calendar

13/05/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
BIOAFFINITY TECHNOLOGIES, INC.	+36.01%	23.03M
BIOMÉRIEUX	-1.29%	12.64B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-0.47%	8.46B
LANTHEUS HOLDINGS, INC.	+22.61%	5.27B
AUTOBIO DIAGNOSTICS CO., LTD.	-2.03%	4.49B
10X GENOMICS, INC.	-53.56%	3.11B
ANDON HEALTH CO., LTD.	+19.30%	2.87B
MYRIAD GENETICS, INC.	+33.07%	2.31B
VITROLIFE AB	-8.42%	2.23B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-3.55%	1.89B

Diagnostic & Testing Substances